iniparib

Iniparib is a small molecule iodobenzamide that was developed as an investigational anticancer agent. It was originally believed to act as an irreversible inhibitor of poly(ADP-ribose) polymerase 1 (PARP1), thereby interfering with DNA repair mechanisms and promoting cell death in tumor cells with DNA damage or mutations such as those involving the ataxia telangiectasia mutated (ATM) gene. However, subsequent research demonstrated that its effects against PARP were not significant and its mechanism of action remains unclear. Iniparib underwent clinical trials for several cancers including triple-negative breast cancer and glioma but failed to show sufficient efficacy in phase III studies and development was discontinued[1][3][5][7].

Other names

4-iodo-3-nitrobenzamidebenzamide 4-iodo-3-nitrobenzamide4-iodo-3-nitrobenzamide-4-iodo-3-nitroBSI 201BSI201BSI-201